The French TV France 5 presents BOYDSense device

In France, more than 3.9 million persons suffer from diabetes.

BOYDSense, the Alpha MOS subsidiary dedicated to medical applications, works on a pain-free device to monitor glucose levels with exhaled breath.

Along with Toulouse CHU, a clinical study has been conducted on 130 patients with Type-2 that measured their glucose level by blood analysis and breath analysis.

Dr. Pierre Gourdy, who is the investigator of the study comments: “More than 98% of the values showed high correlation between blood testing and breath measurement. The results are very promising.”

See the report in the Magazine de la santé on France 5 – June 16, 2023 (10:34)

About BOYDSense

BOYDSense, Inc. is a medical technology company developing affordable, non-invasive tools for measuring critical biomarkers via exhaled breath. Its mission is to build the platform for anywhere, anytime biosignature capture and display to help consumers better manage their conditions. Breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using them to diagnose and monitor chronic diseases, such as diabetes. The BOYDSense platform will also allow consumers and healthcare providers to use breath as a non-invasive medium to detect and monitor diseases like cancer, obesity, asthma, and others. BOYDSense’s first product under development, the g-Sense Breath Meter, is an affordable handheld device that allows people with diabetes to accurately measure blood glucose values through breath-based VOCs without the cost, pain, and social stigma associated with conventional fingerstick glucose testing. BOYDSense is an Alpha MOS company, the leader in volatile organic compound analysis.

For more information, please visit: